Cue Biopharma (CUE) Projected to Post Earnings on Wednesday

Cue Biopharma (NASDAQ:CUE) is projected to release its earnings data on Wednesday, March 26th. Analysts expect Cue Biopharma to post earnings of ($0.15) per share and revenue of $1.70 million for the quarter.

Cue Biopharma Stock Performance

Shares of Cue Biopharma stock opened at $1.03 on Tuesday. The company’s 50 day moving average price is $1.24 and its two-hundred day moving average price is $1.17. The firm has a market capitalization of $65.25 million, a P/E ratio of -1.14 and a beta of 1.88. Cue Biopharma has a fifty-two week low of $0.45 and a fifty-two week high of $2.26. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.